Indian pediatrics · 2015
Sevelamer Hydrochloride for Tumor Lysis Syndrome-related Hyperphosphatemia.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Prasada Harsha L
Аннотация
BACKGROUND: Tumour lysis syndrome is associated with high levels of uric acid, phosphate and potassium along with low levels of calcium and abnormal renal function. Sevelamer, an oral phosphate-binder is used in the treatment of hyperphosphatemia in children and adults on hemodialysis.
CASE CHARACTERISTICS: Two children with T-cell acute lymphoblastic leukemia who presented with a high tumour load and developed tumour lysis syndrome.
OBSERVATION: Both children received Rasburicase and Sevelamer hydrochloride. The serum phosphate reduced to normal levels within 24-48 hrs of initiation of sevelamer hydrochloride.
MESSAGE: Sevelamer appears to be an effective treatment for hyperphosphatemia associated with tumour lysis syndrome.
CASE CHARACTERISTICS: Two children with T-cell acute lymphoblastic leukemia who presented with a high tumour load and developed tumour lysis syndrome.
OBSERVATION: Both children received Rasburicase and Sevelamer hydrochloride. The serum phosphate reduced to normal levels within 24-48 hrs of initiation of sevelamer hydrochloride.
MESSAGE: Sevelamer appears to be an effective treatment for hyperphosphatemia associated with tumour lysis syndrome.